2024-01 – Q4 2023 Reporting
After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down. Recruitment of patients in Australia remains very…
After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down. Recruitment of patients in Australia remains very…
Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study. To facilitate enrolment, the entrance criteria will be revised for the…
Address: Stokholmsgade 412100 Copenhagen E June 21, 2023, at 15:00Please reserve the date
Read more here Norwegian VPS registred shareholders: VPS General Meeting
Serodus ASA - Publishes 2022 Annual Report Download it here
Serodus has visited all clinical centers in Australia and New Zealand SER150/placebo dosing period has been prolonged from 3 to 6 months. Read more here
Transition to the new Australian based CRO was finalized during Q3.Australian ethical committee has approved increasing dosing period from 3 to 6 months.Reactivation of Australian centers by the new CRO.Centers…
European Patent office has Published a SER150 patent 19th October 2022Download